X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA NOVARTIS PLETHICO PHARMA/
NOVARTIS
 
P/E (TTM) x -1.1 350.0 - View Chart
P/BV x 0.0 17.2 0.1% View Chart
Dividend Yield % 0.0 1.7 -  

Financials

 PLETHICO PHARMA   NOVARTIS
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
NOVARTIS
Mar-16
PLETHICO PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs395982 40.2%   
Low Rs31556 5.6%   
Sales per share (Unadj.) Rs604.4252.9 239.0%  
Earnings per share (Unadj.) Rs32.562.1 52.3%  
Cash flow per share (Unadj.) Rs51.363.3 81.1%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs473.6363.6 130.2%  
Shares outstanding (eoy) m34.0831.96 106.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.0 11.6%   
Avg P/E ratio x6.612.4 53.0%  
P/CF ratio (eoy) x4.212.2 34.2%  
Price / Book Value ratio x0.52.1 21.3%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m7,26224,580 29.5%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m1,5961,801 88.6%   
Avg. sales/employee Rs ThNM10,748.9-  
Avg. wages/employee Rs ThNM2,395.2-  
Avg. net profit/employee Rs ThNM2,641.1-  
INCOME DATA
Net Sales Rs m20,5988,083 254.8%  
Other income Rs m386829 46.6%   
Total revenues Rs m20,9848,913 235.4%   
Gross profit Rs m2,818234 1,203.1%  
Depreciation Rs m64237 1,750.1%   
Interest Rs m1,5932 88,511.1%   
Profit before tax Rs m9691,025 94.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m-138752 -18.4%   
Profit after tax Rs m1,1071,986 55.7%  
Gross profit margin %13.72.9 472.1%  
Effective tax rate %-14.373.4 -19.5%   
Net profit margin %5.424.6 21.9%  
BALANCE SHEET DATA
Current assets Rs m18,87712,678 148.9%   
Current liabilities Rs m11,8962,433 489.0%   
Net working cap to sales %33.9126.7 26.7%  
Current ratio x1.65.2 30.5%  
Inventory Days Days3633 109.9%  
Debtors Days Days19822 879.7%  
Net fixed assets Rs m9,86169 14,249.3%   
Share capital Rs m341160 213.2%   
"Free" reserves Rs m12,33111,460 107.6%   
Net worth Rs m16,13911,621 138.9%   
Long term debt Rs m4,7060-   
Total assets Rs m33,14614,400 230.2%  
Interest coverage x1.6570.5 0.3%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.60.6 110.7%   
Return on assets %8.113.8 59.0%  
Return on equity %6.917.1 40.1%  
Return on capital %12.323.6 52.1%  
Exports to sales %21.40.7 2,869.8%   
Imports to sales %15.218.6 81.9%   
Exports (fob) Rs m4,40260 7,313.0%   
Imports (cif) Rs m3,1361,503 208.7%   
Fx inflow Rs m4,402186 2,363.1%   
Fx outflow Rs m3,1841,821 174.9%   
Net fx Rs m1,219-1,635 -74.5%   
CASH FLOW
From Operations Rs m2,4372,531 96.3%  
From Investments Rs m-6,265-8,270 75.8%  
From Financial Activity Rs m2,490-386 -645.6%  
Net Cashflow Rs m-1,337-6,125 21.8%  

Share Holding

Indian Promoters % 82.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.3 2.0 215.0%  
FIIs % 5.5 1.6 343.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 21.5 34.9%  
Shareholders   10,665 41,647 25.6%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   GSK PHARMA  ASTRAZENECA PHARMA  BIOCON LTD  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Infosys Surges 3% on Buyback News(09:30 am)

Majority of Asian stock indices are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.26% while the Hang Seng is up 0.05%.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS